In nis JE was earlier sub cutaneous not it's IM max limit is 2 years w

In nis JE was earlier sub cutaneous not it's IM max limit is 2 years which starin was used earlier and which is used now

Reading File

Finding Sources

Searching the Web

Japanese encephalitis vaccine India national immunization schedule SA 14-14-2 IM subcutaneous strain earlier

Finding Sources

Searching the Web

"JE vaccine" India schedule changed subcutaneous to intramuscular 2020 age limit 15 years

Here's what's established about the Japanese Encephalitis (JE) vaccine in India's National Immunization Schedule (NIS):

Route change (SC → IM) In the original Universal Immunization Programme (UIP) rollout, the JE vaccine was given by the subcutaneous (SC) route, 0.5 mL. This was later revised, and it is now given by the intramuscular (IM) route in the current schedule — in line with the broader standardization of injection routes across the UIP vaccines. Under the current NIS, JE vaccine is given as two doses:

JE-1: 9–12 months (co-administered with MCV-1/measles-rubella)
JE-2: 16–24 months (co-administered with MCV-2/DPT booster)

The "up to 2 years" limit you're referring to is consistent with this — the primary two-dose schedule and catch-up vaccination under UIP is completed by 24 months of age, after which children falling outside this window are managed under the outbreak/campaign strategy rather than the routine two-dose infant schedule.

Strain change (earlier vs. now)

Earlier: JE control in India relied on older inactivated, mouse-brain-derived vaccines (e.g., Nakayama strain-based killed vaccines), which were reactogenic, expensive to produce, and not used for mass routine immunization in India.
Now: India uses the live attenuated SA 14-14-2 strain JE vaccine, manufactured in China (Chengdu Institute of Biological Products) and later also produced indigenously. This strain was first used in mass catch-up campaigns in high-burden districts of UP/Bihar starting 2006, and was formally introduced into routine UIP immunization in 2011 across 181 endemic districts as a single dose for the 1–15 year campaign strategy, later restructured into the current 2-dose infant schedule (JE-1, JE-2) described above.

So in short: Nakayama (older, inactivated, mouse-brain-derived) → SA 14-14-2 (current, live attenuated), and the injection route moved from SC → IM.

One caveat: I could not pull up the exact line in Park's Textbook of PSM (the usual primary source for Indian NIS specifics) confirming the precise wording "IM max limit 2 years" you're quoting from your notes/coaching material — that phrasing sounds like it's from a specific exam-prep table. If you can share which source (Park's edition, IAP schedule, or a coaching note) that line is from, I can cross-check it more precisely against the textbook content in the library.

What is jenvac

Searching the Web

JENVAC Japanese encephalitis vaccine Bharat Biotech strain Kolar

Finding Sources

JENVAC is an indigenous, Indian-made Japanese Encephalitis (JE) vaccine manufactured by Bharat Biotech.

Key facts:

Type: Inactivated (killed), Vero cell-derived vaccine (not live attenuated)
Strain: Made from an Indian JE virus strain — Kolar strain (821564XY), isolated and characterized in collaboration with the National Institute of Virology (NIV), India
Dosing: Given as a single dose in the primary schedule (unlike the two-dose SA 14-14-2 schedule used in the UIP), though booster considerations exist
Protection: Claims cross-protection against genotypically diverse JE virus strains circulating globally, not just the Kolar strain
Use: Primarily used in the private market in India for both pediatric and adult immunization; it is not the vaccine used in the government's Universal Immunization Programme (UIP) — the UIP uses the live attenuated SA 14-14-2 strain vaccine (imported from China, later also produced by Indian Immunologicals) as discussed earlier.

So to summarize the landscape of JE vaccines in India:

Vaccine	Type	Strain	Setting
SA 14-14-2	Live attenuated	Chinese SA 14-14-2 strain	Government UIP (routine 2-dose schedule)
JENVAC (Bharat Biotech)	Inactivated, Vero cell-derived	Indian Kolar strain	Private market, single dose
Older Nakayama-based vaccines	Inactivated, mouse-brain-derived	Nakayama strain	Historical/pre-UIP use, largely phased out

JENVAC is notable as India's first indigenously developed and manufactured inactivated JE vaccine, developed through a partnership between Bharat Biotech and NIV Pune.

This is a shared conversation. Sign in to Orris to start your own chat.